|Mr. Michael F. Bigham||Chairman & CEO||663.43k||N/A||1958|
|Dr. Evan Loh||Pres, Chief Medical Officer, COO & Director||620.78k||N/A||1959|
|Mr. Douglas W. Pagán||Chief Financial Officer||457.82k||N/A||1972|
|Mr. William M. Haskel||Sr. VP, Gen. Counsel & Corp. Sec.||569.77k||N/A||1962|
|Mr. Adam Woodrow||Chief Commercial Officer & VP||466.27k||N/A||1967|
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Paratek Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 September 2018 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 6; Compensation: 10.